

Luca Antonioli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7775337/publications.pdf>

Version: 2024-02-01

148
papers

6,117
citations

87888

38
h-index

82547

72
g-index

149
all docs

149
docs citations

149
times ranked

9239
citing authors

#	ARTICLE	IF	CITATIONS
1	CD39 and CD73 in immunity and inflammation. Trends in Molecular Medicine, 2013, 19, 355-367.	6.7	914
2	Immunity, inflammation and cancer: a leading role for adenosine. Nature Reviews Cancer, 2013, 13, 842-857.	28.4	612
3	Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities. Trends in Cancer, 2016, 2, 95-109.	7.4	177
4	Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?. Acta Neuropathologica, 2018, 136, 345-361.	7.7	167
5	Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation. Frontiers in Immunology, 2017, 8, 36.	4.8	151
6	Adenosine and inflammation: what's new on the horizon?. Drug Discovery Today, 2014, 19, 1051-1068.	6.4	139
7	Adenosine signalling in diabetes mellitusâ€™ pathophysiology and therapeutic considerations. Nature Reviews Endocrinology, 2015, 11, 228-241.	9.6	133
8	Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease. Journal of Medicinal Chemistry, 2017, 60, 3656-3671.	6.4	131
9	Adenosine signaling and the immune system: When a lot could be too much. Immunology Letters, 2019, 205, 9-15.	2.5	130
10	Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders. Current Drug Targets, 2012, 13, 842-862.	2.1	128
11	The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases. Pharmacological Reviews, 2019, 71, 345-382.	16.0	115
12	Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing. FASEB Journal, 2015, 29, 3626-3637.	0.5	106
13	Regulation of enteric functions by adenosine: Pathophysiological and pharmacological implications. , 2008, 120, 233-253.		103
14	Inhibition of Adenosine Deaminase Attenuates Inflammation in Experimental Colitis. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 435-442.	2.5	96
15	Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon. PLoS ONE, 2015, 10, e0144630.	2.5	96
16	Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: A review. Clinical Therapeutics, 2009, 31, 1426-1453.	2.5	92
17	Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?. Progress in Neurobiology, 2020, 191, 101806.	5.7	87
18	Crohnâ€™s Disease and Ulcerative Colitis Show Unique Cytokine Profiles. Cureus, 2017, 9, e1177.	0.5	86

#	ARTICLE	IF	CITATIONS
19	Alteration of colonic excitatory tachykinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Journal of Neuroinflammation</i> , 2016, 13, 146.	7.2	77
20	NKG2A and COVID-19: another brick in the wall. <i>Cellular and Molecular Immunology</i> , 2020, 17, 672-674.	10.5	72
21	Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2876.	4.1	67
22	Cyclooxygenase-1 Is Involved in Endothelial Dysfunction of Mesenteric Small Arteries From Angiotensin II-Infused Mice. <i>Hypertension</i> , 2007, 49, 679-686.	2.7	66
23	Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. <i>Drug Discovery Today</i> , 2017, 22, 1686-1696.	6.4	66
24	The role of purinergic pathways in the pathophysiology of gut diseases: Pharmacological modulation and potential therapeutic applications. , 2013, 139, 157-188.		60
25	Pharmacological modulation of adenosine system: Novel options for treatment of inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 566-574.	1.9	57
26	Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1407-1414.	2.2	56
27	Adenosine metabolism, immunity and joint health. <i>Biochemical Pharmacology</i> , 2018, 151, 307-313.	4.4	54
28	Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. <i>Translational Neurodegeneration</i> , 2019, 8, 5.	8.0	54
29	Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche. <i>Frontiers in Immunology</i> , 2017, 8, 305.	4.8	52
30	Enteric Dysfunctions in Experimental Parkinsons Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 233-243.	2.5	49
31	The Blockade of Adenosine Deaminase Ameliorates Chronic Experimental Colitis through the Recruitment of Adenosine A _{2A} and A ₃ Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 434-442.	2.5	47
32	The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity. <i>PLoS ONE</i> , 2018, 13, e0195502.	2.5	47
33	Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity. <i>Frontiers in Pharmacology</i> , 2018, 9, 1094.	3.5	46
34	Myeloid cells in the tumor microenvironment: Role of adenosine. <i>Oncolmmunology</i> , 2016, 5, e1108515.	4.6	45
35	Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one Ring System as a Useful Template To Obtain Potent Adenosine Deaminase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1681-1692.	6.4	44
36	NSAID-Induced Enteropathy: Are the Currently Available Selective COX-2 Inhibitors All the Same?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 86-95.	2.5	44

#	ARTICLE	IF	CITATIONS
37	Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1216292.	4.6	42
38	Differential recruitment of high affinity A1 and A2A adenosine receptors in the control of colonic neuromuscular function in experimental colitis. <i>European Journal of Pharmacology</i> , 2011, 650, 639-649.	3.5	41
39	Involvement of the P2X7 Purinergic Receptor in Colonic Motor Dysfunction Associated with Bowel Inflammation in Rats. <i>PLoS ONE</i> , 2014, 9, e116253.	2.5	41
40	Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1781-1791.	3.0	41
41	The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 179-191.	3.4	41
42	Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 284-291.	3.7	41
43	Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review. <i>Nutrition Research Reviews</i> , 2018, 31, 239-247.	4.1	40
44	A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 117-122.	1.9	39
45	Influence of the Serotonin Transporter 5HTTLPR Polymorphism on Symptom Severity in Irritable Bowel Syndrome. <i>PLoS ONE</i> , 2013, 8, e54831.	2.5	37
46	Enteric Î±-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson's disease before brain pathology. <i>Npj Parkinson's Disease</i> , 2022, 8, 9.	5.3	36
47	Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. <i>Frontiers in Pharmacology</i> , 2018, 9, 1340.	3.5	35
48	Enteric Glia at the Crossroads between Intestinal Immune System and Epithelial Barrier: Implications for Parkinson Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9199.	4.1	35
49	Differential Role of Cyclooxygenase 1 and 2 Isoforms in the Modulation of Colonic Neuromuscular Function in Experimental Inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 938-945.	2.5	34
50	Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms. <i>Pharmacological Research</i> , 2011, 63, 59-67.	7.1	34
51	A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. <i>Frontiers in Pharmacology</i> , 2018, 9, 1405.	3.5	33
52	Rethinking Communication in the Immune System: The Quorum Sensing Concept. <i>Trends in Immunology</i> , 2019, 40, 88-97.	6.8	33
53	Allopurinol adherence among patients with gout: an Italian general practice database study. <i>International Journal of Clinical Practice</i> , 2015, 69, 757-765.	1.7	31
54	Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia. <i>FASEB Journal</i> , 2020, 34, 5512-5524.	0.5	31

#	ARTICLE	IF	CITATIONS
55	Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. <i>Pharmacological Research</i> , 2016, 104, 186-196.	7.1	30
56	A 2A adenosine receptors control pancreatic dysfunction in high-fat diet-induced obesity. <i>FASEB Journal</i> , 2017, 31, 4985-4997.	0.5	30
57	Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors. <i>Purinergic Signalling</i> , 2017, 13, 497-510.	2.2	30
58	Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1296-1305.	2.4	30
59	Control of enteric neuromuscular functions by purinergic A ₃ receptors in normal rat distal colon and experimental bowel inflammation. <i>British Journal of Pharmacology</i> , 2010, 161, 856-871.	5.4	29
60	An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 485-500.	3.6	29
61	A Purinergic Trail for Metastases. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 277-290.	8.7	28
62	Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. <i>Neurobiology of Disease</i> , 2020, 139, 104821.	4.4	28
63	NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications. <i>Medicinal Research Reviews</i> , 2021, 41, 1890-1926.	10.5	28
64	Intestinal epithelial barrier and neuromuscular compartment in health and disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 1564-1597.	3.3	28
65	Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity. <i>International Journal of Obesity</i> , 2019, 43, 331-343.	3.4	27
66	Role of the A _{2B} receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats. <i>British Journal of Pharmacology</i> , 2014, 171, 1314-1329.	5.4	26
67	Quorum sensing in the immune system. <i>Nature Reviews Immunology</i> , 2018, 18, 537-538.	22.7	26
68	Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects. <i>Drug Safety</i> , 2016, 39, 903-924.	3.2	25
69	P2X4 receptors, immunity, and sepsis. <i>Current Opinion in Pharmacology</i> , 2019, 47, 65-74.	3.5	24
70	Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3523.	4.1	24
71	Hypoxia-inducible-factor-1 in trauma and critical care. <i>Journal of Critical Care</i> , 2017, 42, 207-212.	2.2	23
72	Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship. <i>Cells</i> , 2020, 9, 1772.	4.1	22

#	ARTICLE	IF	CITATIONS
73	The role of P2Y receptors in regulating immunity and metabolism. <i>Biochemical Pharmacology</i> , 2021, 187, 114419.	4.4	22
74	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1323.	2.4	20
75	Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity. <i>Cells</i> , 2020, 9, 1245.	4.1	20
76	Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. <i>Purinergic Signalling</i> , 2018, 14, 27-36.	2.2	19
77	High Levels of α -Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-16.	4.0	18
78	Adenosine Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1270, 145-167.	1.6	18
79	Adenosine and inflammation: it's time to (re)solve the problem. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 43-55.	8.7	18
80	Inflammation and Vascular Ageing: From Telomeres to Novel Emerging Mechanisms. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 321-329.	2.2	17
81	Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling. <i>Obesity</i> , 2020, 28, 609-615.	3.0	17
82	Adenosine pathway and cancer: where do we go from here?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 973-977.	3.4	16
83	Protective effects of the combination <i>Bifidobacterium longum</i> plus lactoferrin against NSAID-induced enteropathy. <i>Nutrition</i> , 2020, 70, 110583.	2.4	16
84	The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5089.	4.1	16
85	Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches. <i>Trends in Molecular Medicine</i> , 2020, 26, 1021-1033.	6.7	16
86	Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2015, 38, 869-888.	3.2	15
87	Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Neuropharmacology</i> , 2017, 123, 22-33.	4.1	15
88	Neuronal regulation of intestinal immune functions in health and disease. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13406.	3.0	15
89	Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases. <i>Frontiers in Pharmacology</i> , 2018, 9, 212.	3.5	15
90	The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis. <i>Cells</i> , 2020, 9, 1509.	4.1	13

#	ARTICLE	IF	CITATIONS
91	Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 748021.	3.5	13
92	Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis. <i>Nutrients</i> , 2021, 13, 608.	4.1	12
93	The ecto-enzymes CD73 and adenosine deaminase modulate 5'-AMP-derived adenosine in myofibroblasts of the rat small intestine. <i>Purinergic Signalling</i> , 2018, 14, 409-421.	2.2	11
94	Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis. <i>Inflammation</i> , 2022, 45, 1829-1847.	3.8	11
95	A holistic view of adenosine in the control of intestinal neuromuscular functions: the enteric "purinome" concept. <i>British Journal of Pharmacology</i> , 2011, 164, 1577-1579.	5.4	10
96	Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease. <i>British Journal of Pharmacology</i> , 2014, 171, 3728-3740.	5.4	10
97	Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 65, 298-308.	2.2	10
98	Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. <i>Digestive and Liver Disease</i> , 2022, 54, 1367-1373.	0.9	10
99	Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 687-703.	5.0	9
100	NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity. <i>British Journal of Pharmacology</i> , 2021, 178, 3924-3942.	5.4	9
101	Risankizumab for the treatment of moderate to severe psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1-8.	3.1	8
102	Inflammatory Bowel Diseases: It's Time for the Adenosine System. <i>Frontiers in Immunology</i> , 2020, 11, 1310.	4.8	7
103	Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?. <i>Frontiers in Pharmacology</i> , 2020, 11, 621955.	3.5	7
104	Adenosine Regulation of the Immune System. , 2018, , 499-514.		6
105	From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinson's disease. <i>European Journal of Histochemistry</i> , 2021, 65, .	1.5	6
106	Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6325.	4.1	5
107	Pharmacological modulation of adenosine receptor pathways and inflammatory disorders: the way towards novel therapeutics?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 717-721.	4.1	4
108	Quality of Adverse Drug Reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilance. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2013, 21, 365-372.	1.6	4

#	ARTICLE	IF	CITATIONS
109	Enteric purinergic signaling: Shaping the "œbrain in the gut". Neuropharmacology, 2015, 95, 477-478.	4.1	4
110	Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy. Pharmacological Reports, 2020, 72, 1347-1357.	3.3	4
111	An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Review of Gastroenterology and Hepatology, 2021, , 1-10.	3.0	4
112	Donepezil improves vascular function in a mouse model of Alzheimer's disease. Pharmacology Research and Perspectives, 2021, 9, e00871.	2.4	4
113	Cathepsin D interacts with adenosine A2A receptors in mouse macrophages to modulate cell surface localization and inflammatory signaling. Journal of Biological Chemistry, 2022, 298, 101888.	3.4	4
114	Tolerability Profiles of Leukotriene Receptor Antagonists and Long-Acting Î²2-Adrenoceptor Agonists in Combination with Inhaled Corticosteroids for Treatment of Asthma: A Review. Journal of Asthma, 2007, 44, 411-422.	1.7	3
115	Tu1889 Targeting of NLRP3 Inflammasome With a Novel Selective Inhibitor as a Suitable Strategy for the Pharmacological Treatment of Bowel Inflammation. Gastroenterology, 2016, 150, S968-S969.	1.3	3
116	P060 Post-inflammatory visceral pain induced by DNBS: Preclinical features for novel therapeutics. Journal of Crohn's and Colitis, 2018, 12, S123-S123.	1.3	3
117	"œCecal Resection with Bipolar Sealing in a Rat Model": A Promising Approach for Future Human Studies. Journal of Investigative Surgery, 2020, 33, 67-68.	1.3	2
118	Editorial: IBD Management" Novel Targets and Therapeutic Perspectives. Frontiers in Pharmacology, 2020, 11, 448.	3.5	2
119	Comment on "œHigh expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma". Tumor Biology, 2015, 36, 7397-7398.	1.8	1
120	Colonic Dysmotility Associated with High Fat Diet-Induced Obesity: Role of the Enteric Glia. Gastroenterology, 2017, 152, S180.	1.3	1
121	The Impact of Gender on Complications and Outcomes of Pelvic Fracture. American Surgeon, 2017, 83, 106-109.	0.8	1
122	Caffeine and Bones: If Less Is Good, More May Not Be Better. Journal of Caffeine and Adenosine Research, 2019, 9, 38-39.	0.6	1
123	Su1903 "œ Early Measurement of Serum Cytokines As Predictor of Clinical and Endoscopic Outcome to Vedolizumab in Patients with Ulcerative Colitis. Gastroenterology, 2019, 156, S-654.	1.3	1
124	Transanal Minimally Invasive Surgery: A Promising Alternative for Certain Advanced Rectal Cancer Patients. Journal of Investigative Surgery, 2019, 32, 377-378.	1.3	1
125	Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease" what about mucosal healing and biomarkers?. Alimentary Pharmacology and Therapeutics, 2020, 52, 751-752.	3.7	1
126	What's new in emergencies, trauma, and shock? Using abdominal computed tomography in geriatric patients on warfarin. Journal of Emergencies, Trauma and Shock, 2018, 11, 71.	0.7	1

#	ARTICLE	IF	CITATIONS
127	Protective Role of Flavonoids Against Colonic Motor Dysfunctions Associated with High Fat Diet-Induced Obesity. <i>Gastroenterology</i> , 2017, 152, S828.	1.3	0
128	Enteric Protective Effects of the Combination Bifidobacterium Longum and Lactoferrin in a Rat Model of Diclofenac-Induced Intestinal Injury. <i>Gastroenterology</i> , 2017, 152, S415.	1.3	0
129	Effects of L-DOPA/Benserazide Co-Treatment on Colonic Dysmotility and Enteric Inflammation Following Dopaminergic Nigrostriatal Neurodegeneration. <i>Gastroenterology</i> , 2017, 152, S179-S180.	1.3	0
130	Mechanisms Underlying the Non-Anticoagulant Effects of Apixaban and Dabigatran on the Integrity of Intestinal Mucosa: A Comparative Pre-Clinical Study. <i>Gastroenterology</i> , 2017, 152, S414-S415.	1.3	0
131	Sa1311 " Anti-Inflammatory and Visceral Pain Relieving Effects of Ar170, a Potent and Selective A3 Receptor Agonist, in a rat Model of Colitis. <i>Gastroenterology</i> , 2019, 156, S-313.	1.3	0
132	1087 " Enteric Inflammation and Altered Colonic Cholinergic Neurotransmission in a Spontaneous Model of Alzheimer's Disease:Timing from Early Phases to Full Disease Development. <i>Gastroenterology</i> , 2019, 156, S-230.	1.3	0
133	P709 Early measurement of serum cytokines as predictor of clinical and endoscopic outcome to vedolizumab in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S475-S475.	1.3	0
134	P.07.3 EARLY MEASUREMENT OF SERUM CYTOKINES AS PREDICTOR OF CLINICAL AND ENDOSCOPIC OUTCOME TO VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS. <i>Digestive and Liver Disease</i> , 2019, 51, e222-e223.	0.9	0
135	1084 " Enteric Alpha-Synuclein Inclusions, Colonic Inflammation, Increased Mucosal Permeability and Alterations of Bowel Neuromuscular Functions Precede Central Neurodegeneration in a Transgenic Mouse Model of Parkinson's Disease. <i>Gastroenterology</i> , 2019, 156, S-229.	1.3	0
136	Higher Body Mass Index and Black Race Increase Risk of Rhabdomyolysis and Acute Kidney Injury After Trauma. <i>Journal of Investigative Surgery</i> , 2020, 33, 291-292.	1.3	0
137	Colonic dysmotility and inflammation associated with high fat diet-induced obesity: role of the enteric glia. <i>Proceedings of the Nutrition Society</i> , 2020, 79, .	1.0	0
138	P454 Serum oncostatin M predicts mucosal healing in Crohn's disease patients treated with infliximab. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S406-S406.	1.3	0
139	Tu1241 SERUM ONCOSTATIN M PREDICTS MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS TREATED WITH INFLIXIMAB. <i>Gastroenterology</i> , 2020, 158, S-1030.	1.3	0
140	T04.01.20 SERUM ONCOSTATIN M PREDICTS MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS TREATED WITH INFLIXIMAB. <i>Digestive and Liver Disease</i> , 2020, 52, S125-S126.	0.9	0
141	DONEPEZIL IMPROVES VASCULAR FUNCTION IN A MOUSE MODEL OF ALZHEIMER'S DISEASE. <i>Journal of Hypertension</i> , 2021, 39, e21.	0.5	0
142	The flavonoid compound luteolin prevents endothelial dysfunction in a mouse model of high fat diet-induced obesity. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-2-47.	0.0	0
143	FA-5, a novel AMP-activated protein kinase (AMPK) activator, as a new pharmacological tool for the management of bowel inflammation. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-5-2.	0.0	0
144	Rifaximin prevents diclofenac-induced enteropathy in rats through antibacterial and anti-inflammatory activities. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-5-28.	0.0	0

#	ARTICLE	IF	CITATIONS
145	A comparative study on the efficacy of NLRP3 inflammasome signaling inhibitors in a pre-clinical model of bowel inflammation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-6-29.	0.0	0
146	Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome. Frontiers in Pharmacology, 2021, 12, 808400.	3.5	0
147	Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab" authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1082-1082.	3.7	0
148	May be adenosine an immuno-quorum-sensing signal?. Purinergic Signalling, 2022, 18, 205-209.	2.2	0